| Attributes | Values |
|---|
| rdf:type
| |
| Description
| - Unmethylated oligodeoxynucleotides containing guanine-cytidine dimers (CpG ODN) were described as potent inducers of selected antitumour immune responses and the immunotherapeutic efficacy of CpG ODN has been examined either alone or as a vaccine adjuvant. We hypothesized that CpG ODN therapy could be effective in immunotherapy of conventional MHC class I+ tumours as well as tumours that lost MHC class I expression during their progression. We employed the animal model resembling MHC class I+ and I- human papilloma virus 16-associated tumours. Immunotherapy with CpG ODN 1826 significantly reduced the growth of MHC class I-proficient and -deficient tumours. We also demonstrated that CpG ODN 1585, which indirectly activate natural killer cells, induced regression of MHC class I- tumours but not I+ tumours. This infers that synthetic CpG ODN have a potential for therapy of MHC class I+ and I- tumours and thus could be also used against tumours with down-regulated MHC class I expression.
- Unmethylated oligodeoxynucleotides containing guanine-cytidine dimers (CpG ODN) were described as potent inducers of selected antitumour immune responses and the immunotherapeutic efficacy of CpG ODN has been examined either alone or as a vaccine adjuvant. We hypothesized that CpG ODN therapy could be effective in immunotherapy of conventional MHC class I+ tumours as well as tumours that lost MHC class I expression during their progression. We employed the animal model resembling MHC class I+ and I- human papilloma virus 16-associated tumours. Immunotherapy with CpG ODN 1826 significantly reduced the growth of MHC class I-proficient and -deficient tumours. We also demonstrated that CpG ODN 1585, which indirectly activate natural killer cells, induced regression of MHC class I- tumours but not I+ tumours. This infers that synthetic CpG ODN have a potential for therapy of MHC class I+ and I- tumours and thus could be also used against tumours with down-regulated MHC class I expression. (en)
- Nemethylované oligodeoxynukleotidy obsahující dimery guaninu a cytidinu (CpG ODN) byly popsány jako silné induktory selektivní protinádorové imunitní odpovědi a byla sledována imunoteraputicka účinnost CpG ODN samotného i jako vakcinačního adjuvans. Předpokládali jsme, že léčba CpG ODN by mohla být účinná i při imunoterapii konvenčních nádorů MHC I+, jakož i nádorů, které během své progrese ztratily expresi molekul MHC 1. třídy. Využili jsme přitom myší model podobající se nádorům MHC I+ a I- vyvolaných lidským papilomavirem 16. Imunoterapie pomocí CpG ODN 1826 výrazně snížila růst nádorů obou typů, MHC I+ a I-. Prokázali jsme také, že CpG ODN 1585, která nepřímo aktivuje přirozené zabíječské buňky, vyvolává regresi nádorů typu MHC I-, ale ne typu MHC I+. Z toho vyplývá, že syntetické CpG ODN mají léčebný potenciál pro imunoterapii nádorů MHC I+ i I- a lze jich tudíž využít k léčbě nádorů se sníženou expresí molekul MHC 1. třídy. (cs)
|
| Title
| - Inhibitory effects of unmethylated CpG oligodeoxynucleotides on MHC class I-deficient and -proficient HPV16-associated tumours
- Inhibitory effects of unmethylated CpG oligodeoxynucleotides on MHC class I-deficient and -proficient HPV16-associated tumours (en)
- Inhibiční účinky nemethylovaných CpG oligodeoxynukleotidů na MHC I+ a MHC I- nádory vyvolané HPV16 (cs)
|
| skos:prefLabel
| - Inhibitory effects of unmethylated CpG oligodeoxynucleotides on MHC class I-deficient and -proficient HPV16-associated tumours
- Inhibitory effects of unmethylated CpG oligodeoxynucleotides on MHC class I-deficient and -proficient HPV16-associated tumours (en)
- Inhibiční účinky nemethylovaných CpG oligodeoxynukleotidů na MHC I+ a MHC I- nádory vyvolané HPV16 (cs)
|
| skos:notation
| - RIV/68378050:_____/06:00024481!RIV06-AV0-68378050
|
| http://linked.open.../vavai/riv/strany
| |
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| - P(GA301/04/0492), Z(AV0Z50520514)
|
| http://linked.open...iv/cisloPeriodika
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/68378050:_____/06:00024481
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - HPV16; immunotherapy; CpG oligodeoxynucleotides (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...odStatuVydavatele
| - DE - Spolková republika Německo
|
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/nazevZdroje
| - International Journal of Cancer
|
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...vavai/riv/projekt
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...v/svazekPeriodika
| |
| http://linked.open...iv/tvurceVysledku
| - Reiniš, Milan
- Bubeník, Jan
- Šímová, Jana
|
| http://linked.open...n/vavai/riv/zamer
| |
| issn
| |
| number of pages
| |
| is http://linked.open...avai/riv/vysledek
of | |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)